Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members in a competitive market, the Swiss Biotech Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources. To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss Biotech™.

Media Info

Our media releases, presentations for the media and useful links

Contact

Swiss Biotech Association
Stauffacherstrasse 16
8004 Zürich
T: +41 44 455 56 78
E-mail

2020

September 21, 2020

Seven outstanding Swiss biotech achievements awarded

Each year, the Swiss Biotech Association awards companies or individuals with the Swiss Biotech Success Stories Awards in recognition of outstanding achievements. Actelion, Debiopharm, Helsinn, Venture Kick, >>Venture>>, Venturelab, and the noble prize-winner Professor Werner Arber receive the awards in 2020.

More on the Swiss Biotech Success Stories

April 21, 2020

Swiss Biotech Report 2020 highlights continued sector growth

Over CHF 1 billion raised for private and public companies – Gene therapy, AI and advanced biologics manufacturing emerging as additional strengths – Licensing deals and collaborations boost revenues – Swiss biotech ecosystem becomes even more diverse
 
With one of the most comprehensive life sciences ecosystems in the world, Swiss biotech continues to thrive. The 2020 edition of the Swiss Biotech Report by the Swiss Biotech Association in conjunction with EY and seven other partners, provides highlights and analysis of funding, M&A and collaborations, as well as a special focus on the exciting new artificial intelligence scene.
 

 

Laureates nominated for the Swiss Biotech Success Story Awards

Each year, the Swiss Biotech Association awards companies or individuals in recognition of outstanding achievements.

The award winners for 2020 are Actelion, Debiopharm, Helsinn, Venture Kick, >>Venture>>, Venturelab, and the noble prize-winner Professor Werner Arber.

Nominated this year for the Swiss Biotech Success Stories Awards in 2021 are Bachem, Basilea, Esbatech, Lonza, and Novimmune.

More on the Swiss Biotech Success Stories

Media releases & presentations 2020

Media release: Seven outstanding Swiss biotech achievements awarded

Download PDF Each year, the Swiss Biotech Association awards companies or individuals…

Sep 21, 2020
Sieben herausragende Schweizer Biotech-Leistungen ausgezeichnet

Download PDF Die Swiss Biotech Association zeichnet jedes Jahr Unternehmen oder…

Sep 21, 2020
Sept avancées remarquables en biotechnologie suisse récompensées

Download PDF Chaque année, la Swiss Biotech Association décerne aux entreprises ou aux…

Sep 21, 2020
Media release: Swiss Biotech Report 2020 highlights continued sector growth

Download PDF Over CHF 1 billion raised for private and public companies Gene therapy,…

Apr 21, 2020
Medienmitteilung: Swiss Biotech Report 2020 – 1,2 Milliarden für Schweizer Biotech-Unternehmen

Download PDF 2019 wurden 1,2 Milliarden Franken in private und öffentliche…

Apr 21, 2020
Communiqué aux médias: Le Swiss Biotech Report 2020 souligne la poursuite de la croissance dans le secteur

Download PDF Plus d’un milliard de CHF ont été levés pour les entreprises…

Apr 21, 2020
Presentation for the media: Swiss Biotech Report 2020

The Swiss Biotech Report media presentation 2020 is only available in English Download PDF

Apr 21, 2020

2019

May 7, 2019

Swiss biotechnology: Investments at record level

The Swiss biotech industry continues to be buoyant and once again managed to increase its sales, exports and research investments in 2018. As a result, it is laying the foundations for further growth and forward-looking development. Capital investment in listed biotech companies saw an especially striking increase: Polyphor boasted one of Europe’s most successful flotations in recent years.
 
May 7, 2019

Awards for outstanding achievements

This year, the Swiss Biotech Association again nominated organizations and people for the “Swiss Biotech Success Stories Awards” in recognition of outstanding achievements:  Nobel Prize winner Prof. Dr. Werner Arber, Actelion, Debiopharm, Helsinn, and biotech startup supporters Venture, Venturelab and Venture Kick.

More on the Swiss Biotech Success Stories

Media releases & presentations 2019

Media release: Swiss biotechnology – Investments at record level and outstanding success stories

Download PDF The Swiss biotech industry continues to be buoyant and once again managed…

May 07, 2019
Medienmitteilung: Schweizer Biotechnologie – Investitionen auf Rekordniveau und ausgezeichnete Erfolgsgeschichten

Download PDF Die Schweizer Biotechindustrie bleibt erfolgreich und konnte ihre…

May 07, 2019
Communiqué de presse: Biotechnologie en Suisse – un niveau record d’investissements et de remarquables success stories

Download PDF Le succès du secteur suisse de la biotechnologie se poursuit. En 2018, il…

May 07, 2019
Presentation for the media: Swiss Biotech Report 2019

The Swiss Biotech Report media presentation 2019 is only available in English Download PDF

May 07, 2019

2018

May 4, 2018

The Swiss Biotech Association honors major industry achievements with Swiss Biotech Success Stories

On the occasion of its 20th anniversary, the Swiss Biotech Association launches Swiss Biotech Success Stories in recognition of the industry’s many accomplishments. Swiss Biotech Success Stories will grow over time to encompass all of the industry’s different facets. An independent jury of experts annually selects the laureates. The first recognitions go to Biogen, Glycart, Okairos, Selexis and Vifor Fresenius Medical Care Renal Pharma for their remarkable achievements and sustainable contributions to Switzerland and its biotech industry. Founders, scientists, investors and business partners celebrated the first laureates yesterday evening at this year’s Swiss Biotech Day.

More on the Swiss Biotech Success Stories

May 3, 2018​

The unbridled success of the Swiss Biotech industry continues apace

The Swiss biotech industry has reached record figures for 2017 in financing, infrastructure investment, and exports. This shows that confidence in its ability to create value and innovate remains unshaken. The most prominent example is the acquisition of Actelion by Johnson & Johnson, which, at almost USD 30 billion, was the largest stock exchange transaction worldwide within the life sciences industry over the past year.

Find the full the media release in 3 languages, as well as the Swiss Biotech Report media presentation below.

More on the Swiss Biotech Report

Media releases & presentations 2018

Media Release: Swiss Biotech Association honors major industry achievements with Swiss Biotech Success Stories

Download PDF On the occasion of its 20th anniversary, the Swiss Biotech Association…

May 04, 2018
Medienmitteilung: Die Swiss Biotech Association honoriert mit Swiss Biotech Success Stories herausragende Branchenerfolge

Download PDF Zum zwanzigjährigen Bestehen ruft die Swiss Biotech Association als…

May 04, 2018
Media Release: The unbridled success of the Swiss Biotech industry continues apace

Download PDF The Swiss biotech industry has reached record figures for 2017 in…

May 03, 2018
Communiqué de presse: Le secteur des biotechnologies a poursuivi son irrésistible ascension

Download PDF L’industrie suisse des biotechnologiesenregistre des chiffres…

May 03, 2018
Medienmitteilung: Ungebremster Höhenflug der Schweizer Biotech-Branche

Download PDF Die Schweizer Biotechindustrie weist für 2017 Rekordwerte bei den…

May 03, 2018
Presentation for the media: Swiss Biotech Report

The Swiss Biotech Report media presentation 2018 is only available in English Download PDF

May 03, 2018